About
Orbsen Therapeutics develops cell therapies based on mesenchymal stromal cells, targeting conditions such as diabetic foot ulcers, acute respiratory distress syndrome, diabetic kidney disease, and primary sclerosing cholangitis. The company is conducting clinical trials, including the NEPHSTROM study, to evaluate its ORBCEL™ cell therapy.
Explore Orbsen Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.